RESUMEN
BACKGROUNDWolfram syndrome is a rare ER disorder characterized by insulin-dependent diabetes mellitus, optic nerve atrophy, and progressive neurodegeneration. Although there is no treatment for Wolfram syndrome, preclinical studies in cell and rodent models suggest that therapeutic strategies targeting ER calcium homeostasis, including dantrolene sodium, may be beneficial.METHODSBased on results from preclinical studies on dantrolene sodium and ongoing longitudinal studies, we assembled what we believe is the first-ever clinical trial in pediatric and adult Wolfram syndrome patients with an open-label phase Ib/IIa trial design. The primary objective was to assess the safety and tolerability of dantrolene sodium in adult and pediatric Wolfram syndrome patients. Secondary objectives were to evaluate the efficacy of dantrolene sodium on residual pancreatic ß cell functions, visual acuity, quality-of-life measures related to vision, and neurological functions.RESULTSDantrolene sodium was well tolerated by Wolfram syndrome patients. Overall, ß cell functions were not significantly improved, but there was a significant correlation between baseline ß cell functions and change in ß cell responsiveness (R2, P = 0.004) after 6-month dantrolene therapy. Visual acuity and neurological functions were not improved by 6-month dantrolene sodium. Markers of inflammatory cytokines and oxidative stress, such as IFN-γ, IL-1ß, TNF-α, and isoprostane, were elevated in subjects.CONCLUSIONThis study justifies further investigation into using dantrolene sodium and other small molecules targeting the ER for treatment of Wolfram syndrome.TRIAL REGISTRATIONClinicalTrials.gov identifier NCT02829268FUNDINGNIH/National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (DK112921, DK113487, DK020579), NIH/National Center for Advancing Translational Sciences (NCATS) (TR002065, TR000448), NIH training grant (F30DK111070), Silberman Fund, Ellie White Foundation, Snow Foundation, Unravel Wolfram Syndrome Fund, Stowe Fund, Eye Hope Foundation, Feiock Fund, Washington University Institute of Clinical and Translational Sciences grant UL1TR002345 from NIH/NCATS, Bursky Center for Human Immunology & Immunotherapy Programs.
Asunto(s)
Dantroleno , Células Secretoras de Insulina , Interleucina-18/análisis , Interleucina-1beta/análisis , Calidad de Vida , Agudeza Visual/efectos de los fármacos , Síndrome de Wolfram , Adolescente , Adulto , Disponibilidad Biológica , Señalización del Calcio/efectos de los fármacos , Niño , Dantroleno/administración & dosificación , Dantroleno/efectos adversos , Dantroleno/farmacocinética , Relación Dosis-Respuesta a Droga , Monitoreo de Drogas/métodos , Humanos , Células Secretoras de Insulina/efectos de los fármacos , Células Secretoras de Insulina/fisiología , Terapia Molecular Dirigida/métodos , Terapia Molecular Dirigida/estadística & datos numéricos , Relajantes Musculares Centrales/administración & dosificación , Relajantes Musculares Centrales/efectos adversos , Relajantes Musculares Centrales/farmacocinética , Examen Neurológico/efectos de los fármacos , Resultado del Tratamiento , Síndrome de Wolfram/diagnóstico , Síndrome de Wolfram/tratamiento farmacológico , Síndrome de Wolfram/metabolismo , Síndrome de Wolfram/fisiopatologíaRESUMEN
The estimation of the drug clearance by aldehyde oxidase (AO) has been complicated because of this enzyme's atypical kinetics and species and substrate specificity. Since human AO (hAO) and cynomolgus monkey AO (mAO) have a 95.1% sequence identity, cynomolgus monkeys may be the best species for estimating AO clearance in humans. Here, O6-benzylguanine (O6BG) and dantrolene were used under anaerobic conditions, as oxidative and reductive substrates of AO, respectively, to compare and contrast the kinetics of these two species through numerical modeling. Whereas dantrolene reduction followed the same linear kinetics in both species, the oxidation rate of O6BG was also linear in mAO and did not follow the already established biphasic kinetics of hAO. In an attempt to determine why hAO and mAO are kinetically distinct, we have altered the hAO V811 and F885 amino acids at the oxidation site adjacent to the molybdenum pterin cofactor to the corresponding alanine and leucine in mAO, respectively. Although some shift to a more monkey-like kinetics was observed for the V811A mutant, five more mutations around the AO cofactors still need to be investigated for this purpose. In comparing the oxidative and reductive rates of metabolism under anaerobic conditions, we have come to the conclusion that despite having similar rates of reduction (4-fold difference), the oxidation rate in mAO is more than 50-fold slower than hAO. This finding implies that the presence of nonlinearity in AO kinetics is dependent upon the degree of imbalance between the rates of oxidation and reduction in this enzyme. SIGNIFICANCE STATEMENT: Although they have as much as 95.1% sequence identity, human and cynomolgus monkey aldehyde oxidase are kinetically distinct. Therefore, monkeys may not be good estimators of drug clearance in humans.
Asunto(s)
Aldehído Oxidasa/metabolismo , Coenzimas/metabolismo , Metaloproteínas/metabolismo , Pteridinas/metabolismo , Aldehído Oxidasa/genética , Animales , Dantroleno/farmacocinética , Evaluación Preclínica de Medicamentos/métodos , Guanina/análogos & derivados , Guanina/farmacocinética , Macaca fascicularis/genética , Cofactores de Molibdeno , Mutagénesis Sitio-Dirigida , Oxidación-Reducción , Homología de Secuencia de Aminoácido , Especificidad de la Especie , Especificidad por Sustrato/genéticaRESUMEN
This study demonstrated that an enteric polymer can mitigate the effects of gastric pH on the oral absorption of a poorly water-soluble weak acid drug, dantrolene (DNT). An amorphous solid dispersion (ASD) of DNT with hydroxypropyl methylcellulose (HPMC) acetate succinate (ASD-HPMCAS) was prepared as the enteric released ASD (ER-SF). ASD with HPMC (ASD-HPMC) and DNT sodium salt were also used as immediate-release supersaturable formulations (IR-SFs) with and without water-soluble polymer, respectively. In vivo study with rats and in vitro study with a dissolution/permeation (D/P) system were performed to evaluate oral DNT absorption from each formulation under normal and high gastric pH conditions in rats and humans, respectively. The oral absorption of DNT from both IR-SFs in rats with a high gastric pH was significantly higher than that in rats with a normal gastric pH. In contrast, ASD-HPMCAS attenuated the difference in oral absorption between normal and high gastric pH conditions with significant improvement of DNT absorption. In vivo results implied that an enteric polymer delayed the onset of dissolution until after gastric emptying. ASD-HPMCAS generated supersaturation in the small intestine irrespective of gastric conditions, which was supported bythe in vitrostudy using the D/P system. This study suggested that an enteric polymer is useful to mitigate the inter- and intra-individual differences in oral absorption of poorly water-soluble weak acid drugs.
Asunto(s)
Dantroleno/farmacocinética , Ácido Gástrico/metabolismo , Relajantes Musculares Centrales/farmacocinética , Polímeros/química , Administración Oral , Animales , Células CACO-2 , Dantroleno/administración & dosificación , Composición de Medicamentos , Humanos , Concentración de Iones de Hidrógeno , Derivados de la Hipromelosa , Absorción Intestinal , Masculino , Metilcelulosa/análogos & derivados , Relajantes Musculares Centrales/administración & dosificación , Ratas , Ratas Sprague-Dawley , SolubilidadRESUMEN
Dantrolene has been demonstrated to be neuroprotective for multiple neurodegenerative diseases. However, dantrolene's limited penetration into the CNS hampers its effectiveness as a neuroprotective agent. Here, we studied whether the intranasal administration of dantrolene provided better penetration into the brain than the commonly used oral approach. C57BL/6 mice, aged 2-4 months, received a single dose of either intranasal or oral dantrolene (5mg/kg). Inhibition of dantrolene clearance from the brain was examined by co-administration with P-gp/BCRP inhibitors, nimodipine or elacridar. The concentration of dantrolene in the brain and plasma was measured at 10, 20, 30, 50, 70, 120, 150 and 180 minutes after administration. Separate cohorts of mice were given intranasal dantrolene (5mg/kg) or vehicle, 3 times/ week, for either 3 weeks or 4 months, to examine potential adverse side effects on olfaction and motor coordination, respectively. We found that Dantrolene concentrations were sustained in the brain after intranasal administration for 180 min, while concentrations fell to zero at 120 min for oral administration. Chronic use of intranasal dantrolene did not impair olfaction or motor function in these mice. Blood brain barrier pump inhibitors did not further increase dantrolene peak concentrations in the brain. Our results suggested that Intranasal administration of dantrolene is an effective route to increase its concentration and duration in the brain compared to the oral approach, without any obvious side effects on olfaction or motor function.
Asunto(s)
Encéfalo/metabolismo , Dantroleno/administración & dosificación , Dantroleno/farmacocinética , Fármacos Neuroprotectores/administración & dosificación , Fármacos Neuroprotectores/farmacocinética , Administración Intranasal , Administración Oral , Animales , Dantroleno/sangre , Femenino , Masculino , Ratones , Ratones Endogámicos C57BL , Fármacos Neuroprotectores/sangre , Distribución TisularRESUMEN
The established analytical method for determining the concentration of dantrolene sodium (Da) in rat tissues by HPLC/MS/MS technique was successfully applied to tissue distribution studies of Da in rats. Tissue homogenate samples were pretreated by protein precipitation with pre-cooled methanol. Chromatographic separation was achieved on an Acquity HPLC column (Kromat Universil XB-C18 , 2.1 × 150 mm, 3 µm). Mass spectrometry was conducted with an electrospray ionization interface in negative ionization mode and multiple reaction monitoring was used for quantitative analysis. The results showed that Da was rapidly and widely distributed in tissues and reached the maximum concentration within 0.5 h in all tissues after oral administration of Da-hydroxypropyl-ß-cyclodextrin (DHC). It was then metabolized by liver and finally excreted from kidney,which indicated that DHC inclusion complex has better absorption and higher oral bioavailability than Da. The results also provided evidence for the safety and effectiveness of drug clinical application.
Asunto(s)
2-Hidroxipropil-beta-Ciclodextrina/química , Cromatografía Líquida de Alta Presión/métodos , Dantroleno , Espectrometría de Masas en Tándem/métodos , Animales , Dantroleno/análisis , Dantroleno/farmacocinética , Límite de Detección , Modelos Lineales , Masculino , Ratas , Ratas Sprague-Dawley , Reproducibilidad de los Resultados , Distribución TisularRESUMEN
Transporters at the blood-brain barrier (BBB) and the blood-cerebrospinal fluid barrier (BCSFB) play a pivotal role as gatekeepers for efflux or uptake of endogenous and exogenous molecules. The protein expression of a number of them has already been determined in the brains of rodents, nonhuman primates, and humans using quantitative targeted absolute proteomics (QTAP). The dog is an important animal model for drug discovery and development, especially for safety evaluations. The purpose of the present study was to clarify the relevance of the transporter protein expression for drug distribution in the dog brain and CSF. We used QTAP to examine the protein expression of 17 selected transporters and receptors at the dog BBB and BCSFB. For the first time, we directly linked the expression of two efflux transporters, P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP), to regional brain and CSF distribution using specific substrates. Two cocktails, each containing one P-gp substrate (quinidine or apafant) and one BCRP substrate (dantrolene or daidzein) were infused intravenously prior to collection of the brain. Transporter expression varied only slightly between the capillaries of different brain regions and did not result in region-specific distribution of the investigated substrates. There were, however, distinct differences between brain capillaries and choroid plexus. Largest differences were observed for BCRP and P-gp: both were highly expressed in brain capillaries, but no BCRP and only low amounts of P-gp were detected in the choroid plexus. Kp,uu,brain and Kp,uu,CSF of both P-gp substrates were indicative of drug efflux. Also, Kp,uu,brain for the BCRP substrates was low. In contrast, Kp,uu,CSF for both BCRP substrates was close to unity, resulting in Kp,uu,CSF/Kp,uu,brain ratios of 7 and 8, respectively. We conclude that the drug transporter expression profiles differ between the BBB and BCSFB in dogs, that there are species differences in the expression profiles, and that CSF is not a suitable surrogate for unbound brain concentrations of BCRP substrates in dogs.
Asunto(s)
Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/metabolismo , Transportador de Casetes de Unión a ATP, Subfamilia G, Miembro 2/metabolismo , Encéfalo/irrigación sanguínea , Capilares/metabolismo , Plexo Coroideo/metabolismo , Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/sangre , Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/líquido cefalorraquídeo , Transportador de Casetes de Unión a ATP, Subfamilia G, Miembro 2/sangre , Transportador de Casetes de Unión a ATP, Subfamilia G, Miembro 2/líquido cefalorraquídeo , Animales , Azepinas/farmacocinética , Transporte Biológico , Barrera Hematoencefálica , Encéfalo/metabolismo , Dantroleno/farmacocinética , Perros , Femenino , Perfilación de la Expresión Génica , Isoflavonas/farmacocinética , Masculino , Proteómica/métodos , Quinidina/farmacocinética , Distribución Tisular , Triazoles/farmacocinéticaRESUMEN
1. This study was designed to evaluate how the absence of P-glycoprotein (Pgp, Mdr1a), breast cancer-resistance protein (Bcrp, Abcg2) or both affects drug distribution into sciatic nerves, brain and cerebrospinal fluid (CSF) in rats. 2. Pgp substrate (loperamide), BCRP substrates (dantrolene and proprietary compound X) and dual substrates (imatinib and proprietary compound Y) were well distributed into sciatic nerves with comparable nerve to plasma concentration ratios between wild-type and knockout (KO) rats. 3. Brain exposure increased substantially in Mdr1a(-/-) rats for loperamide and in Mdr1a(-/-)/Abcg2(-/-) rats for imatinib and compound Y, but minimally to modestly in Abcg2(-/-) rats for dantrolene and compound X. The deletion of Mdr1a or Abcg2 alone had little effect on brain distribution of compound Y. 4. While CSF to unbound brain concentration ratio remained ≥3 in the KO animals for dantrolene, compounds X and Y, it was reduced to 1 in the Mdr1a(-/-)/Abcg2(-/-) rats for imatinib. 5. The data indicate that Pgp and Bcrp do not play significant roles in drug distribution into peripheral nerve tissues in rats, while working in concert to regulate brain penetration. Our results further support that CSF concentration may not be a good surrogate for unbound brain concentration of efflux substrates.
Asunto(s)
Subfamilia B de Transportador de Casetes de Unión a ATP/metabolismo , Transportadoras de Casetes de Unión a ATP/metabolismo , Encéfalo/metabolismo , Dantroleno/farmacocinética , Loperamida/farmacocinética , Nervio Ciático/metabolismo , Subfamilia B de Transportador de Casetes de Unión a ATP/genética , Transportador de Casetes de Unión a ATP, Subfamilia G, Miembro 2 , Transportadoras de Casetes de Unión a ATP/genética , Animales , Dantroleno/farmacología , Loperamida/farmacología , Masculino , Ratas , Ratas Sprague-Dawley , Ratas TransgénicasRESUMEN
Transporter gene knockout rat models are attracting increasing interest for mechanistic studies of new drugs as transporter substrates or inhibitors in vivo. However, limited data are available on the functional validity of such models at the blood-brain barrier. Therefore, the present study evaluated Mdr1a [P-glycoprotein (P-gp)], Bcrp, and combined Mdr1a/Bcrp knockout rat strains for the influence of P-gp and breast cancer resistance protein (BCRP) transport proteins on brain penetration of the selective test substrates [(14)C]WEB 2086 (3-[4-(2-chlorophenyl)-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo-[4,3-a][1,4]-diazepin-2-yl]-1-(4-morpholinyl)-1-propanon) for P-gp and dantrolene for BCRP. Brain-to-plasma concentration ratios (BPR) were measured after intravenous coinfusions of 5.5 µmol/kg per hour [(14)C]WEB 2086 and 2 µmol/kg per hour dantrolene for 2 hours in groups of knockout or wild-type rats. Compared with wild-type controls, mean BPR of [(14)C]WEB 2086 increased 8-fold in Mdr1a knockouts, 9.5-fold in double Mdr1a/Bcrp knockouts, and 7.3-fold in zosuquidar-treated wild-type rats, but was unchanged in Bcrp knockout rats. Mean BPR of dantrolene increased 3.3-fold in Bcrp knockouts and 3.9-fold in double Mdr1a/Bcrp knockouts compared with wild type, but was unchanged in the Mdr1a knockouts. The human intestinal CaCo-2 cell bidirectional transport system in vitro confirmed the in vivo finding that [(14)C]WEB 2086 is a substrate of P-gp but not of BCRP. Therefore, Mdr1a, Bcrp, and combined Mdr1a/Bcrp knockout rats provide functional absence of these efflux transporters at the blood-brain barrier and are a suitable model for mechanistic studies on the brain penetration of drug candidates.
Asunto(s)
Subfamilia B de Transportador de Casetes de Unión a ATP/deficiencia , Transportadoras de Casetes de Unión a ATP/deficiencia , Azepinas/farmacocinética , Encéfalo/metabolismo , Dantroleno/farmacocinética , Triazoles/farmacocinética , Subfamilia B de Transportador de Casetes de Unión a ATP/genética , Transportador de Casetes de Unión a ATP, Subfamilia G, Miembro 2 , Transportadoras de Casetes de Unión a ATP/genética , Animales , Azepinas/sangre , Células CACO-2 , Dantroleno/sangre , Dibenzocicloheptenos/farmacología , Técnicas de Inactivación de Genes , Humanos , Masculino , Quinolinas/farmacología , Ratas , Triazoles/sangreRESUMEN
The pharmacokinetics of dantrolene and its active metabolite, 5-hydroxydantrolene, after a single oral dose of either 5 or 10 mg/kg of dantrolene was determined. The effects of exposure to dantrolene and 5-hydroxydantrolene on activated whole-blood gene expression of the cytokines interleukin-2 (IL-2) and interferon-γ (IFN-γ) were also investigated. When dantrolene was administered at a 5 mg/kg dose, peak plasma concentration (Cmax ) was 0.43 µg/mL, terminal half-life (t1/2 ) was 1.26 h, and area under the time-concentration curve (AUC) was 3.87 µg·h/mL. For the 10 mg/kg dose, Cmax was 0.65 µg/mL, t1/2 was 1.21 h, and AUC was 5.94 µg·h/mL. For all calculated parameters, however, there were large standard deviations and wide ranges noted between and within individual dogs: t1/2 , for example, ranged from 0.43 to 6.93 h, Cmax ratios ranged from 1.05 to 3.39, and relative bioavailability (rF) values ranged from 0.02 to 1.56. While activated whole-blood expression of IL-2 and IFN-γ as measured by qRT-PCR was markedly suppressed following exposure to very high concentrations (30 and 50 µg/mL, respectively) of both dantrolene and 5-hydroxydantrolene, biologically and therapeutically relevant suppression of cytokine expression did not occur at the much lower drug concentrations achieved with oral dantrolene dosing.
Asunto(s)
Dantroleno/administración & dosificación , Dantroleno/farmacocinética , Perros/metabolismo , Relajantes Musculares Centrales/administración & dosificación , Relajantes Musculares Centrales/farmacocinética , Administración Oral , Animales , Área Bajo la Curva , Estudios Cruzados , Dantroleno/sangre , Dantroleno/farmacología , Perros/sangre , Relación Dosis-Respuesta a Droga , Femenino , Regulación de la Expresión Génica/efectos de los fármacos , Semivida , Interferón gamma/genética , Interferón gamma/metabolismo , Interleucina-2/genética , Interleucina-2/metabolismo , Relajantes Musculares Centrales/sangre , Relajantes Musculares Centrales/farmacologíaRESUMEN
The aim of this research was to characterize both the dissolution and precipitation kinetics of a model poorly water soluble drug, dantrolene, from its dissolution data, and to develop a predictive model for its oral pharmacokinetics. Physiologically based pharmacokinetic (PBPK) models were coupled with biorelevant dissolution and precipitation data to predict PK profiles of dantrolene in fasted humans. The paddle method was used to obtain the dissolution profiles of free acid form of dantrolene, dantrolene sodium, and the corresponding commercial product in biorelevant media. The Noyes-Whitney model was used to describe the dissolution kinetics, and a first-order equation was employed for estimating the precipitation kinetics from these dissolution profiles. The PBPK model was set up using STELLA software. After an initial phase of dissolution, the concentration of dantrolene in FaSSGF and FaSSIF-V2 started to decrease again. From the overall dissolution profiles, the dissolution rate constant based on the Noyes-Whitney theory for dissolution and the first-order precipitation rate constant were calculated. The PK profiles predicted under consideration of the precipitation were close to the observed PK profile. By contrast, when only the dissolution was considered, the absorption rate was overestimated. These results indicate that PBPK modeling with dissolution and precipitation kinetics is useful for the predicting the PK profile after oral administration of dantrolene from the sodium salt and suggests a way forward for predicting PK profiles of other salts of weak acids that are poorly soluble.
Asunto(s)
Simulación por Computador , Dantroleno/administración & dosificación , Dantroleno/farmacocinética , Modelos Biológicos , Administración Oral , Predicción , Vaciamiento Gástrico/efectos de los fármacos , Vaciamiento Gástrico/fisiología , Humanos , Masculino , Sales (Química) , Solubilidad/efectos de los fármacosRESUMEN
Dantrolene is a skeletal muscle relaxant used commonly in performance horses to prevent exertional rhabdomyolysis. The goal of the study reported here was to begin to characterize cytochrome P450-mediated metabolism of dantrolene in the horse and describe the pharmacokinetics of the compound, formulated as a capsule or a compounded paste formulation, following oral administration. Dantrolene is rapidly metabolized to 5-hydroxydantrolene both in vivo and in vitro. Preliminary work with equine liver microsomes suggest that two enzymes are responsible for the metabolism of dantrolene, as evidenced by two distinct K(m) values, one at high and one at low substrate concentrations. For the pharmacokinetic portion of the study, a randomized, balanced 2-way crossover design was employed wherein eight healthy horses received a single oral dose of either capsules or paste followed by a 4 week washout period prior to administration of the second formulation to the same horse. Blood samples were collected at time 0 (prior to drug administration) and at various times up to 96 h postdrug administration. Plasma samples were analyzed using liquid chromatography-mass spectrometry and data analyzed using both noncompartmental and compartmental analysis. Peak plasma concentrations were 28.9 ± 21.6 and 37.8 ± 12.8 ng/mL for capsules and paste, respectively and occurred at 3.8 h for both formulations. Dantrolene and its major metabolite were both below the limit of detection in both plasma and urine by 168 h postadministration.
Asunto(s)
Dantroleno/farmacocinética , Caballos/metabolismo , Relajantes Musculares Centrales/farmacocinética , Administración Oral , Animales , Cápsulas , Cromatografía Líquida de Alta Presión/veterinaria , Estudios Cruzados , Dantroleno/administración & dosificación , Dantroleno/análogos & derivados , Dantroleno/metabolismo , Femenino , Masculino , Espectrometría de Masas/veterinaria , Microsomas Hepáticos/metabolismo , Relajantes Musculares Centrales/administración & dosificación , Relajantes Musculares Centrales/metabolismo , Pomadas , Distribución Aleatoria , Factores de TiempoRESUMEN
REASONS FOR PERFORMING STUDY: Dantrolene sodium is used to prevent exertional rhabdomyolysis in predisposed horses. Food intake might negatively impact dantrolene bioavailability in horses; however, prolonged feed restriction might be detrimental to performance. OBJECTIVE: To determine a minimum duration of feed restriction that would optimise plasma dantrolene concentrations in horses after nasogastric administration. It was hypothesised that feed restriction for 4, 8 or 12 h before dantrolene administration would result in higher plasma dantrolene concentrations than achieved with no feed restriction before treatment. METHODS: Five healthy horses were randomly rotated through 4 feed restriction periods of 0, 4, 8 and 12 h duration prior to nasogastric administration of dantrolene sodium (6 mg/kg bwt). Plasma dantrolene concentration was measured by spectrofluorometry at 60, 90, 120, 150, 180 and 210 min after administration. Data were analysed via repeated measures ANOVA. RESULTS: Peak plasma dantrolene concentration was highest when horses had 0 and 4 h of feed restriction (0.65 ± 0.10 µg/ml at 120 min; 0.66 ± 0.17 at 180 min, respectively) and was lower when horses were restricted from feed for 8 h (0.45 ± 0.15 at 150 min) and 12 h (0.21 ± 0.09 at 180 min). Mean plasma dantrolene concentration did not differ between 0 and 4 h feed restriction at any sample time, but feed restriction for 8 h resulted in significantly lower plasma dantrolene concentration at 60 and 180 min after treatment than when horses were restricted 0 and 4 h, respectively. Plasma dantrolene concentration was significantly lower at all sample times when horses were restricted from feed 12 h compared to 0 or 4 h. CONCLUSIONS: Absorption of nasogastrically administered dantrolene is inhibited by feed restriction before administration. To achieve optimal plasma dantrolene concentrations, feed restriction before oral administration should not exceed 4 h.
Asunto(s)
Dantroleno/sangre , Dantroleno/farmacocinética , Privación de Alimentos , Caballos/sangre , Relajantes Musculares Centrales/sangre , Relajantes Musculares Centrales/farmacocinética , Animales , Femenino , Masculino , Factores de TiempoRESUMEN
A synergistic effect of P-glycoprotein (P-gp)/Abcb1a and breast cancer resistance protein (Bcrp)/Abcg2 was reported to limit the brain penetration of their common substrates. This study investigated this based on pharmacokinetics using Mdr1a/1b(-/-), Bcrp(-/-), and Mdr1a/1b(-/-)/Bcrp(-/-) mice. Comparison of the brain- and testis-to-plasma ratios (C(brain)/C(plasma) and C(testis)/C(plasma), respectively) of the reference compounds quinidine and dantrolene for P-gp and Bcrp, respectively, indicates that impairment of either P-gp and Bcrp did not cause any change in the efflux activities of Bcrp or P-gp, respectively, at both the blood-brain barrier (BBB) and blood-testis barrier (BTB). The C(brain)/C(plasma) and C(testis)/C(plasma) of the common substrates erlotinib, flavopiridol, and mitoxantrone were markedly increased in Mdr1a/1b(-/-)/Bcrp(-/-) mice even compared with Mdr1a/1b(-/-) and Bcrp(-/-) mice. Efflux activities by P-gp and Bcrp relative to passive diffusion at the BBB and BTB were separately evaluated based on the C(brain)/C(plasma) and C(testis)/C(plasma) in the knockout strains to the wild-type strain. P-gp made a larger contribution than Bcrp to the net efflux of the common substrates, but Bcrp activities were also significantly larger than passive diffusion. These parameters could reasonably account for the marked increase in C(brain)/C(plasma) and C(testis)/C(plasma) in the Mdr1a/1b(-/-)/Bcrp(-/-) mice. In conclusion, the synergistic effect of P-gp and Bcrp on C(brain)/C(plasma) and C(testis)/C(plasma) can be explained by their contribution to the net efflux at the BBB and BTB without any interaction between P-gp and Bcrp.
Asunto(s)
Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/metabolismo , Transportadoras de Casetes de Unión a ATP/metabolismo , Antineoplásicos/farmacocinética , Encéfalo/metabolismo , Flavonoides/farmacocinética , Mitoxantrona/farmacocinética , Proteínas de Neoplasias/metabolismo , Piperidinas/farmacocinética , Inhibidores de Proteínas Quinasas/farmacocinética , Quinazolinas/farmacocinética , Testículo/metabolismo , Subfamilia B de Transportador de Casetes de Unión a ATP , Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/genética , Transportador de Casetes de Unión a ATP, Subfamilia G, Miembro 2 , Transportadoras de Casetes de Unión a ATP/genética , Algoritmos , Animales , Antimaláricos/farmacocinética , Barrera Hematoencefálica/efectos de los fármacos , Dantroleno/farmacocinética , Clorhidrato de Erlotinib , Cinética , Masculino , Ratones , Ratones Noqueados , Relajantes Musculares Centrales/farmacocinética , Proteínas de Neoplasias/genética , Quinidina/farmacocinética , Distribución Tisular , Xenobióticos/metabolismoRESUMEN
El dantrolene (DNL) es el fármaco de elección para prevenir y revertir los síntomas de la hipertermia maligna (HM); es un derivado liposoluble de la hidantoína que relaja y paraliza totalmente al músculo esquelético. La HM es un síndrome que produce estragos fisiológicos. La identificación de los pacientes sensibles a hipertermia maligna (SHM) puede prevenir el desencadenamiento de este síndrome evitando el uso de agentes anestésicos y relajantes que lo inducen. El dantrolene ejerce su efecto miorrelajante disminuyendo la frecuencia de reapertura de los canales de calcio del retículo sarcoplásmico a través del receptor de ryanodina (RYI), disminuyendo el calcio en el sarcoplasma y de este modo la exitación-contracción, con un efecto agonista dopaminérgico. El dantrolene se metaboliza en el hígado y aunque atraviesa la barrera placentaria, no se han reportado efectos adversos en neonatos. La mortalidad de la HM, sin la administración del dantrolene era del 95 por ciento y solo se podía hacer un tratamiento sintomático. La aplicación de este medicamento, sumado a un diagnóstico precoz y un tratamiento específico, ha reducido la mortalidad a un 3 por ciento. El síndrome de hipertermia maligna (SHM) se presenta con: taquicardia, aumento de CO2, taquipnea, rigidez muscular, arritmias cardíacas, acidosis respiratoria y metabólica, aumento de la temperatura corporal, tensión arterial inestable, cianosis, mioglobinuria, oliguria y rigidez del músculo masetero (RMM). También puede ocurrir como un síndrome serotoninérgico, o ser causado por intoxicación por IMAO, anfetaminas, cocaína o CO. Se adjuntan tres casos clínicos donde se utilizó con éxito el DNL.
Dantrolene (DNL) is the medication of choice to prevent and to revert the symptoms of the malignant hyperthermia(HM), it is a liposoluble derivative of the hydantoine that relaxes and paraIyzes totally the skeletal muscle. HM is a syndrome that produces physiological devastations. The identification of the sensitive patients to hyperthermia malignant (SHM) can anticipate the triggering of these cases avoiding the use of anaesthesic and relaxing agents who induce it. The miorelaxing effect diminishes the frequency of reopening of the calcium channels of the reticulum sarcoplasmatic across the ryanodine receptor (RYI), diminishing the calcium in the sarcoplasma and hereby it reduce the excitation-contraction, resulting in agonist dopaminergic effect. DNL is metabolized in the liver. It crosses the placental barrier; nevertheless adverse effects have not been reported in neonates. The mortality in the HM without the specific drug was 95 percent, it was possible to do only symptomatic treatment. The application of this medicine, added to an early diagnosis and a specific treatment, has reduced the mortality to 3 percent. The syndrome of hyperthermia malignant (SHM) appears with: tachycardia, increase of CO2, taquipnea, muscular inflexibility, cardiac arrhythmias, respiratory and metabolic acidosis, increase of the corporal temperature, arterial unstable tension, cyanosis, mioglobinuria, oliguria and inflexibility of the masseter muscle (RMM). Also it can happen as a serotoninergic syndrome, poisoning for IMAO, anfetamines, cocaine and poisoning from CO. Three clinical cases are included where the DNL was in use successfully.
O dantrolene (DNL) é o fármaco de escolha para a prevençao e reversao dos sintomas da hipertermia maligna (HM); e um derivado lipossolúvel da hidantoína que relaxa e paralisa totalmente o músculo esquelético. A HM é uma síndrome que causa enormes danos fisiológicos; a identificaçao dos pacientes sensíveis à hipertermia maligna (SHM) pode prevenir o desencadeamento dessa síndrome evitando o uso de agentes anestésicos e relaxantes que a induzem. O daxtrolene exerce seu efeito miorrelaxante diminuindo a freqüência de reabertura dos canais de cálcio do reticulo sarcoplásmico através do receptor da ryanodina (RYI) e reduzindo o cálcio no sarcoplasma, e, conseqüentemente, também a excitaçao-contraçao, com efeito agonista dopaminérgico. E metabolizado pelo fígado, e apesar de atravessar a barreira placentária, nao se informaram efeitos adversos em neonatos. A mortalidade da HM sem a administraçao de dantrolene era de 95 por cento, e apenas era possivel o tratamento sintomático. A aplicaçao deste medicamento, junto a um diagnóstico precoce e tratamento específico, tem diminuída a mortalidade a 3 por cento. A síndrome de hipertermia maligna (SHM) associa-se a: taquicardia, aumento do CO2, taquipnéia, rigidez muscular, arritmias cardíacas, acidose respiratória e metabólica, aumento da temperatura corporal, tensao arterial instável, cianose, mioglobinúria, oligúria e rigidez do músculo masseter (RMM). Também pode-se apresentar como síndrome serotoninérgica, intoxicaçao por IMAO, anfetaminas, cocaína e intoxicaçao por CO. Sao informados três casos clínicos nos quais se utilizou o DNL.
Asunto(s)
Humanos , Masculino , Animales , Femenino , Dantroleno/administración & dosificación , Dantroleno/efectos adversos , Dantroleno/farmacocinética , Dantroleno/farmacología , Dantroleno/uso terapéutico , Anestesia General/efectos adversos , Anestésicos por Inhalación/efectos adversos , Diagnóstico Precoz , Halotano , Hipertermia Maligna/diagnóstico , Hipertermia Maligna/etiología , Hipertermia Maligna/prevención & control , Hipertermia Maligna/tratamiento farmacológicoRESUMEN
Dantrolene is the only drug proven effective for prevention and treatment of malignant hyperthermia (MH). Current dosing recommendations are based on noncompartmental analyses and are largely empiric. They are also divergent, as evidenced by differing recommendations from the Malignant Hyperthermia Association of the United States (MHAUS) and European Sources. We determined the compartmental pharmacokinetics of dantrolene, simulated the concentration time course based on currently recommended dosing, and suggest an optimal regimen. Nine volunteers (55-89 kg) received IV infusions of dantrolene (5 mg/kg over 30 min followed by 0.05 mg.kg(-1) . h(-1) for 5 h). Venous blood samples were drawn for up to 60 h, and dantrolene plasma concentrations were determined by reverse phase, high-performance liquid chromatography. One, two, and three compartmental models were fitted to the data, and a covariate analysis was performed. All calculations were performed with NONMEM using the population approach. The data were adequately described by a two-compartment model with the following typical variable values (median +/- se): volumes of distribution V1= 3.24 +/- 0.61 L; V2= 22.9 +/- 1.53 L; plasma clearance CL el= 0.03 +/- 0.003 L/min; and distributional clearance CL dist= 1.24 +/- 0.22 L/min. All parameters were scaled linearly with weight. Simulations of European recommendations for treatment of MH lead to plasma concentrations converging to 14-18 mg/L within 24 h. Simulating MHAUS guidelines (intermittent bolus administration) yielded peak and trough plasma concentrations ranging from 6.7-22.6 mg/L. Based on our findings, we propose an infusion regimen adjusted to the initial bolus dose(s) required to control symptoms. This strategy maintains the individualized therapeutic concentrations and improves stability of plasma concentrations.
Asunto(s)
Dantroleno/farmacocinética , Hipertermia Maligna/tratamiento farmacológico , Adulto , Simulación por Computador , Dantroleno/administración & dosificación , Femenino , Guías como Asunto , Humanos , Masculino , Hipertermia Maligna/metabolismo , Modelos BiológicosRESUMEN
Rapid and efficient cooling is the most important therapeutic objective in patients with heat stroke (HS). This article reviews the mechanism of action and rationale for the use of dantrolene as a potential supportive cooling method in the treatment of HS. Relevant studies were included to support discussion of the role of dantrolene for the treatment of HS. In some studies dantrolene was shown to accelerate cooling rate when administered after the development of exertional HS. Dantrolene was also found to be effective in reducing the extent of HS signs when given as pretreatment in an animal model. Accumulated data do not support the routine use of dantrolene as an adjuvant cooling technique in HS, but administration of this drug in severe cases, or in which no improvement is observed, appears rational. Further trials are needed in order to assess the true effectiveness of dantrolene in HS.
Asunto(s)
Dantroleno/uso terapéutico , Fiebre/tratamiento farmacológico , Golpe de Calor/tratamiento farmacológico , Hipotermia Inducida , Relajantes Musculares Centrales/uso terapéutico , Enfermedad Hepática Inducida por Sustancias y Drogas/etiología , Dantroleno/efectos adversos , Dantroleno/farmacocinética , Femenino , Fiebre/terapia , Semivida , Golpe de Calor/terapia , Humanos , Masculino , Relajantes Musculares Centrales/efectos adversos , Relajantes Musculares Centrales/farmacocinéticaRESUMEN
Human malignant hyperthermia is a life-threatening genetic sensitivity of skeletal muscles to volatile anaesthetics and depolarizing neuromuscular blocking drugs occurring during or after anaesthesia. The skeletal muscle relaxant dantrolene is the only currently available drug for specific and effective therapy of this syndrome in man. After its introduction, the mortality of malignant hyperthermia decreased from 80% in the 1960s to < 10% today. It was soon discovered that dantrolene depresses the intrinsic mechanisms of excitation-contraction coupling in skeletal muscle. However, its precise mechanism of action and its molecular targets are still incompletely known. Recent studies have identified the ryanodine receptor as a dantrolene-binding site. A direct or indirect inhibition of the ryanodine receptor, the major calcium release channel of the skeletal muscle sarcoplasmic reticulum, is thought to be fundamental in the molecular action of dantrolene in decreasing intracellular calcium concentration. Dantrolene is not only used for the treatment of malignant hyperthermia, but also in the management of neuroleptic malignant syndrome, spasticity and Ecstasy intoxication. The main disadvantage of dantrolene is its poor water solubility, and hence difficulties are experienced in rapidly preparing intravenous solutions in emergency situations. Due to economic considerations, no other similar drugs have been introduced into routine clinical practice.
Asunto(s)
Dantroleno/farmacología , Hipertermia Maligna/tratamiento farmacológico , Relajantes Musculares Centrales/farmacología , Dantroleno/farmacocinética , Dantroleno/uso terapéutico , Humanos , Relajantes Musculares Centrales/farmacocinética , Relajantes Musculares Centrales/uso terapéutico , Síndrome Neuroléptico Maligno/tratamiento farmacológicoRESUMEN
The present study was designed to investigate the effects of dantrolene on intracellular Ca(2+) ([Ca(2+)](i)) handling and inotropy in rat infarcted myocardium. Dantrolene-treated rats with myocardial infarction were placed into two different dosage groups. The infarcted control group received placebo only. Isometric contractility and intracellular Ca(2+) transients were recorded simultaneously in isolated papillary muscles. Diastolic [Ca(2+)](i) was significantly lower in muscle preparations from infarcted rats receiving dantrolene compared to the placebo control group. Additionally, treatment with dantrolene in infarcted rats significantly improved the inotropic response to 10(-4) M isoproterenol. The protein levels of the sarcoplasmic reticulum Ca(2+) ATPase were increased in infarcted rat hearts with dantrolene treatment. We conclude that dantrolene improved the inotropic response to beta-adrenoceptor stimulation in rat postinfarcted myocardium, which is related to improved intracellular Ca(2+) handling, and lowered diastolic Ca(2+) concentration.
Asunto(s)
Calcio/metabolismo , Dantroleno/farmacocinética , Contracción Miocárdica/efectos de los fármacos , Infarto del Miocardio/tratamiento farmacológico , Animales , Western Blotting , Proteínas de Unión al Calcio/química , Proteínas de Unión al Calcio/metabolismo , ATPasas Transportadoras de Calcio/química , ATPasas Transportadoras de Calcio/metabolismo , Ciclofilinas/química , Ciclofilinas/metabolismo , Dantroleno/administración & dosificación , Ventrículos Cardíacos/química , Ventrículos Cardíacos/metabolismo , Inyecciones Intraperitoneales , Contracción Isométrica/efectos de los fármacos , Masculino , Infarto del Miocardio/patología , Tamaño de los Órganos/efectos de los fármacos , Ratas , Ratas Endogámicas Lew , ATPasas Transportadoras de Calcio del Retículo Sarcoplásmico , Factores de TiempoRESUMEN
Malignant hyperthermia (MH) is a genetic, potentially life-threatening disorder of the skeletal muscle presenting during or following general anaesthesia. Trigger agents are volatile anaesthetics and depolarising muscle relaxants. Dantrolene is the only available drug for effective and specific MH therapy, which reduces significantly the mortality rate. Dantrolene is a skeletal muscle relaxant that depresses the excitation-contraction coupling,however, the specificity of action remains unknown. Recent studies identified the ryanodine receptor, the calcium release channel of the sarcoplasmic reticulum, as the direct molecular target of dantrolene. In addition to its use for MH, dantrolene is used in other disorders such as neuroleptic malignant syndrome and spasticity. Since dantrolene is weakly water soluble, the clinical preparation is time and manpower consuming. New agents have been synthesized, but because of economic considerations no registration for clinical usage has been realised.
Asunto(s)
Dantroleno/farmacología , Dantroleno/uso terapéutico , Relajantes Musculares Centrales/farmacología , Relajantes Musculares Centrales/uso terapéutico , Dantroleno/efectos adversos , Dantroleno/química , Dantroleno/farmacocinética , Interacciones Farmacológicas , Alucinógenos/envenenamiento , Humanos , Hipertermia Maligna/tratamiento farmacológico , Relajantes Musculares Centrales/efectos adversos , Relajantes Musculares Centrales/química , Relajantes Musculares Centrales/farmacocinética , Espasticidad Muscular/tratamiento farmacológico , N-Metil-3,4-metilenodioxianfetamina/envenenamiento , Síndrome Neuroléptico Maligno/tratamiento farmacológicoRESUMEN
In our study, effects of dantrolene sodium on glucose 6-phosphate dehydrogenase (G6PD) were examined in the human erythrocytes in vitro and in rat erythrocytes in vivo. Human erythrocyte G6PD was purified using ammonium sulfate fractionation and 2',5'-ADP Sepharose 4B affinity chromatography. The enzyme activity was determined by Beutler's method. The overall purification procedures gave the human G6PD having the specific activity of 97.6 EU/mg of protein, which was purified 9760-fold with a yield of 39%. Dantrolene sodium inhibited the enzyme activity under in vitro conditions and the I(50) value (drug concentration which produces 50% inhibition) of this drug was 0.91 mM. In vivo studies were performed in rats (Sprague-Dawley). Dantrolene sodium at 10 mg/kg inhibited the enzyme activity significantly (p < 0.05) 3 h after dosing. We conclude that dantrolene sodium showed inhibitory effect on G6PD activity both in vitro and in vivo.